Consideration of the validity of ramelteon for Tourette's syndrome.
Not Applicable
- Conditions
- Tourette's syndrome
- Registration Number
- JPRN-UMIN000023891
- Lead Sponsor
- Akita University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
1) Having a history of other neurological and psychiatric disorders that can affect the motor and psychological function. 2) Having a distinct focal lesion on the brain MRI. 3) Patient who had change in the treatment within 4 weeks prior to the registration. 4) Patient who had been medicated ramelteon in the past. 5) Having liver dysfunction. 6) Having severe sleep apnea syndrome. 7) Taking an administration of fluvoxamine maleate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy; Yale Global Tic Severity Scale (0W, 2W, 6W, 8W)
- Secondary Outcome Measures
Name Time Method Y-BOCS, GTS-QOL, pattern of sleep Safety; Adverse events and adverse effects (vital sign, laboratory data)